Abstract An elevated level of homocysteine called hyperhomocysteinemia (HHcy) is associated with pathological cardiac remodeling. Hydrogen sulfide (H 2 S) acts as a cardioprotective gas; however, the mechanism by which H 2 S mitigates homocysteine-mediated pathological remodeling in cardiomyocytes is unclear. We hypothesized that H 2 S ameliorates HHcy-mediated hypertrophy by inducing cardioprotective miR-133a in cardiomyocytes. To test the hypothesis, HL1 cardiomyocytes were treated with (1) plain medium (control, CT), (2) 100 lM of homocysteine (Hcy), (3) Hcy with 30 lM of H 2 S (Hcy ? H 2 S), and (4) H 2 S for 24 h. The levels of hypertrophy markers: c-fos, atrial natriuretic peptide (ANP), and beta-myosin heavy chain (b-MHC), miR-133a, and its transcriptional inducer myosin enhancer factor-2C (MEF2C) were determined by Western blotting, RT-qPCR, and immunofluorescence. The activity of MEF2C was assessed by co-immunoprecipitation of MEF2C with histone deacetylase-1(HDAC1). Our results show that H 2 S ameliorates homocysteine-mediated up-regulation of c-fos, ANP, and b-MHC, and downregulation of MEF2C and miR-133a. HHcy induces the binding of MEF2C with HDAC1, whereas H 2 S releases MEF2C from MEF2C-HDAC1 complex causing activation of MEF2C. These findings elicit that HHcy induces cardiac hypertrophy by promoting MEF2C-HDAC1 complex formation that inactivates MEF2C causing suppression of anti-hypertrophy miR-133a in cardiomyocytes. H 2 S mitigates hypertrophy by inducing miR-133a through activation of MEF2C in HHcy cardiomyocytes. To our knowledge, this is a novel mechanism of H 2 S-mediated activation of MEF2C and induction of miR-133a and inhibition of hypertrophy in HHcy cardiomyocytes. 
Introduction
Homocysteine (Hcy) is a sulfur-containing non-protein coding amino acid that contributes to cardiovascular diseases [1, 2] . Elevated level of Hcy is called hyperhomocysteinemia (HHcy), which is associated with increased incidence of mortality [3] . It is considered that 5 lM/L raise in plasma Hcy level increases the risk of coronary artery disease by as much as 0.5 mmol/L of cholesterol [4] . HHcy differentially regulates miRNAs [5] and attenuates beta-adrenergic signaling by suppressing stimulatory G protein (Gs) [6] , which lead to pathological cardiac remodeling. HHcy is caused due to either impaired re-methylation process, which involves methyl tetrahydrofolate reductase enzyme and folic acid and B vitamins co-factors, or defect in any of the three Hcy metabolic enzymes: cystathionine b-synthase (CBS), cystathionine c-lyase (CSE), and 3-mercaptopyruvate sulfur transferase (3MST). These three enzymes convert Hcy into hydrogen sulfide (H 2 S) [7] . Contrary to HHcy, H 2 S is a cardioprotective gas [8] [9] [10] [11] . H 2 S ameliorates cardiac dysfunction at several levels. It preserves mitochondrial function in myocardial ischemia-reperfusion injury [12] , suppresses activation of nuclear factor kappa B and mitogenactivated protein kinases in Coxsackie virus B3-infected rat cardiomyocytes [13] , mitigates endoplasmic reticulum stress in high-fat diet-fed mice [14] , induces Nrf2 transcription factor to alleviate oxidative stress in myocardial ischemia [15] , and up-regulates endothelial nitric oxide synthase for nitric oxide bioavailability in ischemia-reperfusion injury [16] . Although the pathological effect of HHcy and the cardioprotective role of H 2 S are well documented, the mechanism by which HHcy induces pathological cardiac remodeling and H 2 S mitigates that remodeling is poorly understood. MicroRNAs (miRs) are newly emerged, tiny, con-coding, regulatory RNAs that modulate gene expression by either mRNA degradation or translational repression [17] . They are recognized as a novel therapeutic target for cardiovascular diseases [18, 19] . In human hearts,[800 miRNAs are present and [250 miRNAs are differentially regulated in pathological hearts [20] . MiR-133a is one of the most abundant miRNAs in the heart [21] . It is cardioprotective and mitigates cardiac fibrosis [22, 23] and hypertrophy [24] . MiR-133a transcription is regulated by myosin enhancer factor 2C (MEF2C) [25] . MEF2 is repressed when they make complex with histone deacetylase (HDAC) [26] . Therefore, the formation of MEF2C-HDAC complex inactivates MEF2C. However, the role of Hcy in formation of MEF2C-HDAC complex and thereby transcription of miR-133a in cardiomyocytes is unclear. Also, whether the H 2 S ameliorates the effect of Hcy on MEF2C-HDAC complex formation and miR-133a deregulation is nebulous. Accordingly, we investigated the role of Hcy on MEF2C-mediated attenuation of miR-133a and H 2 S in restoring the level of miR-133a in HHcy cardiomyocytes.
Materials and methods
Cell culture and treatments HL1 cardiomyocytes were cultured in Claycomb media as described elsewhere [5] . In brief, cells are treated with only incomplete (serum-deprived) medium (control, CT), Hcy (100 lm), and/or H 2 S (30 lm) in the incomplete medium for 24 h. We selected 100 lm dose of Hcy because at in vitro level, lower dose of Hcy (30 lm) did not engender significant effect on pathological remodeling in cardiomyocytes [5] . It is also reported that inborn errors of Hcy metabolism result into elevation of plasma Hcy level from 200 to 300 lm/L, which is markedly higher than the mild elevation ([15 lm/L) of Hcy in humans [27] . Therefore, 100 lm is physiologically relevant dose of Hcy. After 24 h, cells were used for either protein extraction or imaging. Hematoxylin-Eosin (H-E) (#HAE-1, ScyTeK laboratories Inc., USA) staining of cells was performed after fixing the cells with 4 % paraformaldehyde. Cells were observed under bright-field color microscope. For inhibiting miR-133a, we used anti-miR-133a oligonucleotide (AMO-133a) (Catalogue #AM17000, ID: AM10413 Ambion, Life technologies Inc., USA). AMO133a was transfected before treatment with Hcy and H 2 S. In brief, 75 pmol AMO-133a was transfected with lipofectamine (6 ll per well of 6-well plate) in a final volume of 300 ll optiMEM (Catalogue #31985-70, Gibco Life technologies Inc., USA) for 8 h. Cells were then treated for Hcy ? H 2 S for 24 h in antibiotic-free medium.
Western blotting
Radio-Immuno-Precipitation Assay (RIPA, catalogue #BP-115D, Boston BioProducts, USA) lysis buffer was used to isolate total protein from HL1 cells after treatment. The quantity of protein was estimated using Pierce BCA protein Assay kit (catalogue #23227, Thermo scientific, USA). Western blotting was performed using SDS-PAGE (10 %). Protein was transferred onto nitrocellulose membrane (catalogue #162-0115, Bio-Rad Laboratories, USA) by overnight transfer at 4°C. The primary antibodies of MEF2C (catalogue #ab79436, Abcam, USA), b-MHC (catalogue #ab172967, Abcam, USA), ANP (catalogue #GTX109255, GeneTex, USA), and b-actin (catalogue #sc-47778, Santa Cruz Biotech, USA) were diluted in the ratio of 1:1000. The secondary antibodies, anti-mouse IgG-HRP (catalogue #sc-2005, Santa Cruz Biotech, USA), and antirabbit IgG-HRP (catalogue #sc-2054, Santa Cruz Biotech, USA) were diluted in the ratio of 1:2000. The membranes were developed, and band intensity was analyzed by ChemiDoc software (Bio-Rad Laboratories, USA).
miRNA assay
For miRNA assay, RNA was isolated from HL1 cells using miRVana TM miRNA Isolation Kit (catalogue #AM1560 Life technologies, USA). The RNAs quality was assessed by NanoDrop 2000c (Thermo Scientific Inc., USA), and RNAs with 260/280 [1.8 and 260/230 [1.8 were used for miR-133a assay using Taqman probes. The miRNA Reverse Transcriptase-PCR followed by Taqman qPCR was performed using miR-133a (Assay ID-002246)-and U6 SnRNA (Assay ID: 001973)-specific primers following the manufacturer's instruction and protocol (Life technologies, USA). The details of the protocol are published elsewhere [28] . U6 SnRNA was used as an endogenous control for miR-133a. The miRNA PCR reaction mixtures were amplified in a 96-well plate in Bio-Rad CFX qPCR Instrument, and data were analyzed by integrated BioRad CFX Manager3.0 software (Bio-Rad Laboratories, USA).
Immunocytochemistry
In vitro immunocytochemistry studies on HL1 cells were performed using standard protocol. In brief, cells were cultured in 24-well plates and treated for 24 h in incomplete medium. After treatment, medium was removed and cells were washed with 19 PBS, pH 7.4 followed by fixation in 4 % paraformaldehyde (catalogue #158127, Sigma, USA) for 40 min. 
Co-immunoprecipitation
Co-immunoprecipitation (co-IP) was performed using dynabeads (catalogue #10003D, Life Technologies, USA) following the protocol from the company. In brief, cells were lysed using IP lysis buffer (Thermo Scientific, USA). Diluted anti-HDAC1 antibody (catalogue #ab46985, Abcam, USA) was added to dynabeads, mixed by gentle shaking, and incubated for 10 min at room temperature. Tubes were placed on a magnet and supernatant was removed. Beads were re-suspended in PBS and washed three times with PBS-Tween-20. Protein samples were added in the tubes and gently pipetted to re-suspend the samples. Tubes were incubated with rotation (15 rpm) for 30 min at room temperature. After incubation, beads were washed and transferred into a new tube. Elution was done with sample buffer having b-mercaptoethanol. 10 % SDS-PAGE was performed and membranes were blotted with MEF2C and HDAC1 antibodies. In another gel, same protein lysates were electrophoresed for b-actin to confirm the equal loading of proteins that was used for immunoprecipitation.
Statistical analysis
The values are represented as mean ± standard error of mean (SE). To determine the statistical significance between the groups, one-way analyses of variance (ANOVA) was performed, which was followed by Newman-Keuls method to determine differences in means between the groups. P \ 0.05 was considered statistically significant.
Results

H 2 S mitigates HHcy-induced hypertrophy in cardiomyocytes
To determine the hypertrophic effect of Hcy on cardiomyocytes, we treated HL1 cells with high dose (100 lM) of Hcy for 24 h as per the published report [29] and determined the expression of b-MHC, ANP, and c-fos. We found that HHcy induces both the early hypertrophy maker c-fos (Fig. 1a) and late hypertrophy markers b-MHC (Fig. 1b) and ANP (Fig. 1c) in the cardiomyocytes. To assess the cardioprotective effect of H 2 S on HHcymediated hypertrophy, the cardiomyocytes were treated with both Hcy and H 2 S (30 lM). Interestingly, the levels of both early and late hypertrophy markers were significantly down-regulated in Hcy-and H 2 S (Hcy ? H 2 S)-treated group as compared to the Hcy group (Fig. 1a-c) suggesting that H 2 S mitigates the initiation and progression of HHcy-mediated hypertrophy in cardiomyocytes. Furthermore, there was no significant difference between CT and H 2 S groups (Fig. 1a-c) suggesting that H 2 S maintains the normal size of the cardiomyocytes. The oneway ANOVA showed significant difference among the mean value of c-fos, ANP, and b-MHC among the groups. These molecular studies clearly show that H 2 S retains the size of healthy cardiomyocytes but has an anti-hypertrophic effect in HHcy cardiomyocytes. To reinforce our results, we observed the changes in cell morphology in the four groups (CT, Hcy, Hcy ? H 2 S, and H 2 S) by H-E staining. Our results show that cells were enlarged and morphology of the cells were more round-shaped in Hcy as compared to the CT, where the shape of the cells was triangular with tapering ends. Notably, in Hcy ? H 2 S, the cell size and morphology were more like CT (Fig. 1d) . These results are consistent with the molecular data that H 2 S alleviates Hcy-mediated hypertrophy in cardiomyocytes (Fig. 1a-c) . In cells, which were treated with H 2 S only, the cell size and morphology were similar to that of the CT cells suggesting that the treated dose of H 2 S did not have any significant effect on the size and morphology of the cardiomyocytes.
HHcy attenuates and H 2 S induces miR-133a in cardiomyocytes
Since miR-133a is recognized as an anti-hypertrophy miRNA [24] and H 2 S is reported to induce miR-133a [30] , we were interested to evaluate the effect of HHcy on miR- For that, we measured the levels of miR-133a in the above-mentioned four groups using individual miR-133a assay as described elsewhere [31] . The miR-133a assay revealed that HHcy down-regulates miR-133a, whereas concomitant treatment with H 2 S induces miR-133a in the cardiomyocytes (Fig. 2a) . However, there was no significant difference between CT and H 2 S groups. One-way ANOVA showed significant difference in miR-133a among the four groups. These findings elucidate that HHcy inhibits miR-133a, which is ameliorated by H 2 S in cardiomyocytes. Since miR-133a inhibits hypertrophy [24] , we were interested to understand whether the mitigation of HHcy-mediated hypertrophy by H 2 S is due to up-regulation of miR-133a. For that, we treated Hcy ? H 2 S with anti-miR-133a (AMO). If H 2 S inhibits HHcy-mediated hypertrophy through induction of miR133a, then treatment with AMO in Hcy ? H 2 S should blunt the anti-hypertrophic effect of H 2 S. We evaluated the levels of b-MHC and ANP in the five (four above and Hcy ? H 2 S ? AMO) groups, which revealed that AMO treatment nullified the anti-hypertrophy effect of H 2 S in HHcy cardiomyocytes (Fig. 2b) . It suggests that miR-133a plays a crucial role in H 2 S-mediated mitigation of hypertrophy in HHcy cardiomyocytes. These results provide evidence that H 2 S inhibits Hcy-mediated hypertrophy by inducing miR-133a in the cardiomyocytes.
H 2 S augments miR-133a by activating MEF2C in HHcy cardiomyocytes
After showing that H 2 S induces miR-133a, we were interested to understand how H 2 S up-regulated miR-133a in HHcy cardiomyocytes. To investigate the underlying mechanism, we first measured the protein and cellular levels of MEF2C-a transcriptional inducer of miR-133a [25] in the four groups. Our results show that HHcy down-regulates, whereas H 2 S induces MEF2C in HHcy cardiomyocytes at both protein and cellular levels (Fig. 3a, b) . However, there was no significant difference between CT and H 2 S groups (Fig. 3a, b) . The significant increase in MEF2C in Hcy ? H 2 S as compared to Hcy group suggests that H 2 S induces miR-133a by up-regulating MEF2C in HHcy cardiomyocytes. Next, we determined whether the Hcy has any effect on activation of MEF2C. Since MEF2C remains inactive if it binds to HDAC [26] , we performed co-IP of MEF2C with HDAC1. The bound form of MEF2C with HDAC1 was evaluated by immunoprecipitation of HDAC1 (input) and probing it with MEF2C. The co-IP analyses revealed that the bound form of MEF2C (MEF2C-HDAC1) was robust in HHcy cardiomyocytes but dramatically decreased in Hcy ? H 2 S (Fig. 3c) . To rule out unequal loading of proteins for co-IP, we separately performed Western blot with the same amount of protein and measured the levels of b-actin, which showed equal loading of proteins in the four groups (Fig. 3c) . To reinforce the co-IP results, we determined the cellular levels of MEF2C and HDAC1 in the four groups. The immunofluorescence results show that HDAC1 was up-regulated in Hcy as compared to CT and mitigated in Hcy ? H 2 S (Fig. 3d(i) ). The cellular expression of MEF2C was less in Hcy but elevated in Hcy ? H 2 S. Interestingly, co-localization of MEF2C with HDAC1 revealed that the number of cells expressing both HDAC1 and MEF2C was comparatively higher in Hcy group (Fig. 3d(i) ). To evaluate the co-expression of MEF2C with HDAC1, we determined the ratio of MEF2C to HDAC1 in the four groups. If the HDAC1 level is higher than MEF2C, there will be more probability of bound (MEF2C-HDAC1) or inactive form of MEF2C. The fluorescence analyses showed that in Hcy group MEF2C/HDAC1 was decreased than that of CT indicating that HHcy induces the formation of MEF2C-HDAC1 complex. On contrary, treatment with H 2 S increased MEF2C and decreased HDAC1, thereby increasing the ratio of MEF2C/HDAC1 and decreasing the bound form of MEF2C in HHcy cardiomyocytes (Fig. 3d(i)-(ii) ). These results demonstrate that HHcy attenuates miR-133a by inhibiting MEF2C, whereas H 2 S up-regulates miR-133a by inducing MEF2C in HHcy cardiomyocytes. Overall, our results show that HHcy down-regulates and inactivates MEF2C causing attenuation of miR-133a, which induces hypertrophy in cardiomyocytes. On contrary, H 2 S up-regulates and activates MEF2C and increases the level of miR-133a that mitigates HHcy-mediated hypertrophy in cardiomyocytes (Fig. 4 ).
Discussion
We demonstrate a novel mechanism of Hcy-mediated inhibition of miR-133a and induction of hypertrophy, and H 2 S-mediated mitigation of hypertrophy in HHcy cardiomyocytes (Fig. 4) . Hcy is reported to play a crucial role in pathological cardiac remodeling [2, 3, 5, 18, [32] [33] [34] . However, there is debate on whether Hcy is a cause or effect of cardiovascular diseases [27] . The negative results of clinical trials, where lowering Hcy level by folic acid supplements did not improve the conditions in heart failure patients, pose a major setback on HHcy being a cause for heart failure [35] [36] [37] . Additionally, the underlying molecular mechanisms that elicit the causative role of Hcy in the heart disease is poorly understood [38] . Our results demonstrate that HHcy induces cardiomyocyte hypertrophy by suppressing miR-133a, which show a causative role of Hcy in pathological remodeling of the heart. Further, we provided a detailed mechanism by which Hcy down-regulates miR-133a. HHcy inactivates and down-regulates MEF2C in the cardiomyocytes (Fig. 3a-c) . Since miR133a is attenuated in the failing human hearts [24] and in diabetic hearts [22, 28] , and its role is established as antihypertrophy [24, 39] and anti-fibrosis [22, 23] , our results suggest a new role of Hcy in miR-133a-mediated pathological remodeling in the heart, which is relevant to the human heart failure.
H 2 S is a metabolic product of Hcy [7] . Mutation of cystathionine beta-synthase or cystathionine gamma-lyase genes or enzymatic inactivation of these proteins impairs the endogenous production of H 2 S [7] . H 2 S is emerged as a novel cardioprotective gas with therapeutic potential for heart diseases [8, 10, 11, 40] . It has multifaceted role such as vasorelaxant [41] , inducer of anti-stress AKT [42, 43] , preserver of mitochondrial function [12] , and inhibitor of hypertrophy and fibrosis [44] . H 2 S also mitigates Hcymediated induction of oxidative and endoplasmic reticulum stress [45] . Since HHcy can be caused due to inhibition of metabolic enzymes that produce H 2 S from Hcy [7] , one of the fundamental questions could be whether the inhibition of H 2 S production is the major cause of HHcy-mediated cardiovascular diseases. To answer this question, we treated cardiomyocytes with both Hcy and H 2 S concomitantly. Our results show that treatment of H 2 S mitigates the hypertrophic effect of Hcy (Fig. 1a-c) supporting the notion that inhibition of H 2 S production in HHcy cardiomyocytes leads to hypertrophy. Since H 2 S is reported to mitigate phenylephrine-mediated hypertrophy by inducing miR-133a in cardiomyocytes [30] , we also measured the levels of miR-133a in HHcy cardiomyocytes treated with and without H 2 S. Our results show that H 2 S mitigates HHcy-mediated attenuation of miR-133a in cardiomyocytes (Fig. 2) suggesting that the effect of HHcy is alleviated by H 2 S in cardiomyocytes. Our results also support the anti-hypertrophic effect of H 2 S in cardiomyocytes [30] . To get insight into how Hcy suppresses and H 2 S induces miR-133a, we measured the levels of MEF2C, a known inducer of miR-133a [25] , in HHcy cardiomyocytes treated with and without H 2 S. Interestingly, we observed that Hcy inactivates MEF2C by promoting the binding of MEF2C with HDAC1 in cardiomyocytes. On contrary, H 2 S treatment mitigates binding of MEF2C with HDAC1 releasing more MEF2C that in turn increases transcription of miR133a in HHcy cardiomyocytes. To our knowledge, this is the first study showing the mechanism of Hcy-and H 2 S-mediated regulation of miR-133a transcription in cardiomyocytes. These findings also suggest that the inhibition of H 2 S could be the major cause of HHcy-mediated pathological remodeling, and supplement of H 2 S could be a major therapeutic strategy to ameliorate Hcy-mediated cardiovascular pathology.
Hypertrophy is a marker for cardiac pathogenesis [46] . Our results show that c-fos, an early marker of hypertrophy [47] , is up-regulated in HHcy cardiomyocytes and mitigated by H 2 S in HHcy cardiomyocytes (Fig. 1a) . Our results are consistent with the previous report showing that HHcy induces c-fos in hepatocytes [48] . HHcy is also reported to induce left ventricular (LV)-to-body weight ratio, which is an indicator of cardiac hypertrophy [49] . Our results show up-regulation of b-MHC and ANP late markers of cardiac hypertrophy in HHcy cardiomyocytes (Fig. 1b-d) supporting HHcy-mediated induction of LV hypertrophy. It is documented that H 2 S mitigates cardiac hypertrophy in pathological hearts [44, 50] , which is consistent with our results, where H 2 S mitigates Hcy-mediated hypertrophy in cardiomyocytes (Fig. 1a-d) . The anti-hypertrophic effect of miR-133a is due to its regulatory effect on RhoA and CDC42, which are involved in cytoskeletal and myofibrillar arrangements during cardiac hypertrophy [24] . One of the key molecules involved in regulation of cardiac remodeling is connective tissue growth factor (CTGF). CTGF regulates collagens synthesis by inducing fibroblast and is a direct target of miR-133a [51] . In cardiomyocytes, knockdown of miR-133a robustly increased the mRNA and protein levels of CTGF, which is blunted by overexpression of miR-133a [51] . Our results show that Hcy induces hypertrophy by suppressing miR-133a, whereas H 2 S mitigates hypertrophy by inducing miR-133a in HHcy cardiomyocytes. The cardioprotective effect of H 2 S is also mediated through miR-21, which attenuates myocardial ischemic and inflammatory injury in mice [52] .
In conclusion, our findings provide new insight into Hcy-mediated down-regulation and inactivation of MEF2C, attenuation of miR-133a, and induction of hypertrophy in cardiomyocytes. It also suggests that the pathophysiology of HHcy is attributed to the decreased levels of H 2 S, and H 2 S has therapeutic potential for HHcy pathogenesis. Our findings also provide a novel mechanism of H 2 S-mediated induction of miR-133a in cardiomyocytes.
